本文由小咖机器人翻译整理

期刊来源：Nat Med

原文链接：https://doi.org/10.1038/s41591-023-02672-2

摘要内容如下：

Semaglutide（一种治疗2型糖尿病（T2DM）和肥胖症的胰高血糖素样肽1受体（GLP1R）激动剂药物）与自杀意念相关的报道引发了欧洲监管机构的调查。在这项来自Trinetx Analytics Network的电子健康记录的回顾性队列研究中，我们旨在评估与非GLP1R激动剂抗肥胖或抗糖尿病药物相比，Semaglutide与自杀意念的相关性。在6个月的随访中，通过比较倾向评分匹配的患者组，计算偶发和复发自杀意念的风险比（HR）和95%置信区间（CI）。研究人群包括240，618名超重或肥胖患者，他们服用了Semaglutide或非GLP1R激动剂抗肥胖药物，在1，589，855名T2DM患者中重复了研究结果。在超重或肥胖患者（平均年龄50.1岁，72.6%为女性）中，与非GLP1R激动剂抗肥胖药物相比，Semaglutide与较低的自杀意念事件（HR=0.27，95%CI=0.200.32-0.600.36）和复发（HR=0.44，95%CI=0.32-0.60）风险相关，在性别、年龄和种族分层中一致。在T2DM患者（平均年龄57.5岁，49.2%为女性）中重复了类似的结果。我们的研究结果并不支持与非GLP1R激动剂抗肥胖或抗糖尿病药物相比，使用Semaglutide产生自杀意念的风险更高。

英文原文如下：

Abstracts

Concerns over reports of suicidal ideation associated with semaglutide treatment, a glucagon-like peptide 1 receptor (GLP1R) agonist medication for type 2 diabetes (T2DM) and obesity, has led to investigations by European regulatory agencies. In this retrospective cohort study of electronic health records from the TriNetX Analytics Network, we aimed to assess the associations of semaglutide with suicidal ideation compared to non-GLP1R agonist anti-obesity or anti-diabetes medications. The hazard ratios (HRs) and 95% confidence intervals (CIs) of incident and recurrent suicidal ideation were calculated for the 6-month follow-up by comparing propensity score-matched patient groups. The study population included 240,618 patients with overweight or obesity who were prescribed semaglutide or non-GLP1R agonist anti-obesity medications, with the findings replicated in 1,589,855 patients with T2DM. In patients with overweight or obesity (mean age 50.1 years, 72.6% female), semaglutide compared with non-GLP1R agonist anti-obesity medications was associated with lower risk for incident (HR = 0.27, 95% CI = 0.200.32-0.600.36) and recurrent (HR = 0.44, 95% CI = 0.32-0.60) suicidal ideation, consistent across sex, age and ethnicity stratification. Similar findings were replicated in patients with T2DM (mean age 57.5 years, 49.2% female). Our findings do not support higher risks of suicidal ideation with semaglutide compared with non-GLP1R agonist anti-obesity or anti-diabetes medications.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。

现在购买可享受最大优惠（买一年送三个月，买两年送一年），2024年2月10日起将不再享有该优惠。